The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study

The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With Hepatic Arterial Infusion Chemotherapy of FOLFOX for HCC: a Retrospective Study

This is a multicenter，retrospective study to explore the effectiveness and safety of Atezo/Bev plus hepatic artery infusion chemotherapy (HAIC) among adult patients with high-risk HCC in real-world clinical practice in China. Eligible patients diagnosed with high-risk HCC initiating the study treatment of interest between 28 October 2020 and 31 June 2025 will be included in this study. Secondary data from medical records of approximately 10 sites across China will be utilized.

Inclusion criteria:

• Aged ≥ 18 years at the initiation of Atezo/Bev plus HAIC

• Initiating Atezo/Bev between 28 October 2020 and 31 June 2025

• Diagnosed with high-risk HCC as evidenced clinically or by radiology, histology or cytology before or at the initiation of Atezo/Bev plus HAIC. The evidence of being diagnosed as "high-risk" was based on the IMbrave 150, including any of the following:

  • tumor invasion of the main trunk or contralateral branch of the portal vein (Vp4)
  • bile duct invasion
  • tumor occupancy of 50% or more of the liver

• At least one visit record after the initiation of Atezo/Bev plus HAIC

Exclusion criteria:

• Diagnosed with concomitant cancer except for basal cell carcinoma before or at the initiation of Atezo/Bev plus HAIC
• Participating in interventional clinical studies before or at initiating Atezo/Bev plus HAIC